HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Church & Dwight Cuts Outlook Due To Rising Costs, Adds Suppliers To Strengthen ‘Weak Links’

Executive Summary

“We expect higher input costs and transportation costs to remain elevated for the rest of the year,” says CEO Matthew Farrell. Firms lowers full-year outlook for net sales growth from previous range of 5% to 6% to around 5%.

You may also be interested in...



Church & Dwight Meets Supply, Inflation Headwinds With Line Extensions, Price Increases

C&D executives didn’t downplay potential challenges during 2022 – including an expected $155m increase in costs from inflation – as they discussed the health, personal and household care manufacturer and marketer’s 2021 full-year and fourth-quarter results and its long-range plans.

Church & Dwight Chews On Strong Growth For Vitafusion As Consumers Stick To Category

Vitafusion gummy vitamins had 24% consumption growth in Q3 and Zicam homeopathic cold remedies had 40%. Church & Dwight plans to increase prices on 80% of portfolio by the end of the 2022 Q1.

US Q3 Consumer Health Earnings Preview: Helm Changes, Supply Challenges, Separation Plan

July-September results for sales of OTC drugs, supplements and personal care products will come with CEO leaving J&J and P&G, a new leader for Perrigo Americas, Bausch Health likely offering Bausch + Lomb separation details and a cloud of rising costs related to supplies.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

RS151612

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel